Zhejiang Shapuaisi Pharmaceutical Co Ltd

Shapuaisi released its 2026 interim report, with total operating revenue of 197 million yuan, down 16.77% year-on-year. Net profit attributable to the parent company was 19.5003 million yuan, down 10.81% from the same period last year. Net cash inflow from operating activities was 910,100 yuan, a sharp year-on-year decline of 98.23%. The company's asset-liability ratio was 24.24% and gross margin was 50.80%, both changed from the same period last year. Diluted earnings per share were 0.05 yuan, down 16.67% year-on-year.

Qilu Pharmaceutical's marketing application for atropine sulfate eye drops, filed under chemical drug registration category 2.2, was accepted by the Center for Drug Evaluation of the National Medical Products Administration on July 24. The indication is to slow the progression of myopia in children. Currently, only Xingqi Pharmaceutical's 0.01% atropine sulfate eye drops have been approved for marketing in this field, in March 2024, with nationwide sales reaching 603.6 million yuan in 2025, a year-on-year increase of 212%. Similar products from companies such as Hengrui Medicine's subsidiary Shengdi Pharmaceutical and Zhaoke Ophthalmology have also entered the marketing application stage, while Ocumension Therapeutics, Shapuaisi, and JMD Biomed are in late-stage clinical trials. Qilu Pharmaceutical stated that it is currently only an application, and the specific launch time is uncertain.